UK markets closed

Ascletis Pharma Inc. (1672.HK)

HKSE - HKSE Delayed price. Currency in HKD
Add to watchlist
0.900-0.010 (-1.10%)
At close: 04:08PM HKT

Ascletis Pharma Inc.

Building D
12th Floor 198 Qidi Road, HIPARK Xiaoshan District
Hangzhou 311200
China
86 571 8538 9730
https://www.ascletis.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees219

Description

Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. The company offers Ritonavir tablet; and ASCLEVIR and GANOVO for the treatment of Hepatitis C virus. It is also developing ASC22 for treating CHB and HIV functional cure; ASC10 for respiratory syncytia virus; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, ASC42, ASC43F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis. In addition, the company is developing ASC40 to treat recurrent glioblastoma; ASC61 for advanced solid tumors; and ASC40, an oral small molecule for the treatment of acne. Ascletis Pharma Inc. was founded in 2013 and is headquartered in Hangzhou, the People's Republic of China.

Corporate governance

Ascletis Pharma Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.